Surgical Ablation of Hepatocellular Carcinoma with 2.45-GHz Microwave: a Critical Appraisal of Treatment Outcomes
Overview
Affiliations
Objective: To evaluate the efficacy and safety of a new generation of 2.45-GHz microwave to ablate hepatocellular carcinoma by surgical approach. DESIGN; Case series with prospective follow-up.
Setting: A university teaching hospital in Hong Kong.
Patients: From March 2009 to January 2011, 26 consecutive patients (19 men and 7 women) with a median age of 63 (range, 49-79) years with hepatocellular carcinoma were recruited. Five (19%) of the patients had recurrent hepatocellular carcinoma after previous treatment.
Intervention: Microwave ablation for hepatocellular carcinomas (one tumour, n=24; two tumours, n=2) using a laparoscopic (n=16) or open approach (n=10).
Main Outcome Measures: Operative mortality and morbidity, rate of incomplete ablation, recurrence rate, and survival rate.
Results: The median tumour diameter was 3.8 cm (range, 2.0-6.0 cm). Complications occurred in five (19%) of the patients; only one was ablation-related, and there was no operative mortality. One (4%) of the patients experienced incomplete ablation. Recurrent tumours were noted in 11 (42%) of the patients (5 were local, 2 were remote, and 4 were multifocal) after a median follow-up of 14 (range, 4-26) months. The failure rate for local disease control was 23%, and was 14% if patients with recurrent hepatocellular carcinoma were excluded. All but one patient survived until the time of censorship. The mean survival was 25 (standard deviation, 1) months.
Conclusion: This new-generation microwave technique is safe and effective for local ablation of hepatocellular carcinoma. It is a valuable treatment option for patients who are not candidates for hepatectomy.
Han X, Ni J, Li S, Deng H, Liang H, Xu Y Abdom Radiol (NY). 2021; 46(8):3758-3771.
PMID: 34032898 DOI: 10.1007/s00261-021-03105-9.
Advanced Techniques in the Percutaneous Ablation of Liver Tumours.
Hui T, Kwan J, Pua U Diagnostics (Basel). 2021; 11(4).
PMID: 33805107 PMC: 8064108. DOI: 10.3390/diagnostics11040585.
Xu Z, Xie H, Zhou L, Chen X, Zheng S Anal Cell Pathol (Amst). 2019; 2019:8619096.
PMID: 31534899 PMC: 6732647. DOI: 10.1155/2019/8619096.
Lee D, Lee J Korean J Radiol. 2018; 19(4):545-559.
PMID: 29962861 PMC: 6005950. DOI: 10.3348/kjr.2018.19.4.545.
Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.
Cheung T, Kwok P, Chan S, Cheung C, Lee A, Lee V Liver Cancer. 2018; 7(1):40-54.
PMID: 29662832 PMC: 5892367. DOI: 10.1159/000485984.